Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07368998 · ClinicalTrials.gov registry record · Phase 2
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 14
- Study locations
NCT07368998: Recruiting Phase 2 study of Breast Cancer, sponsored by Hoffmann-La Roche.
NCT07368998 is a Phase 2 study of Breast Cancer that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 80 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 14 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07368998, a Phase 2 study of Breast Cancer, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (LA/mBC) in the post-cyclin-dependent kinase inhibitor (CDKi) setting.
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG Inavolisib
Study Locations (14)
Other
- Cliniques Universitaires St-Luc - Brussels
- UZ Leuven Gasthuisberg - Leuven
- Vall d?Hebron Institute of Oncology (VHIO), Barcelona - Barcelona
- Hospital Universitario San Cecilio - Granada
- Hospital Universitario 12 De Octubre - Madrid
- Hospital Clinico Universitario de Valencia - Valencia
- Adana Baskent University Hospital - Adana
- Memorial Ankara Hastanesi - Ankara
- Medical Park Seyhan Hospital - Seyhan
- Princess Alexandra Hospital - Harlow
- Mount Vernon Cancer Centre - Northwood, Middlesex
California
- Los Angeles Cancer Network - Los Angeles
New Jersey
- Astera Cancer Care East Brunswick - East Brunswick
Istanbul
- Bagcilar Medipol Mega Universitesi Hastanesi - Bağcılar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-02-18 |
| Est. Completion | 2031-10-31 |
| Phase | Phase 2 |
What NCT07368998 shows while recruiting
NCT07368998 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fulvestrant is the first listed.
NCT07368998 lists 14 locations in 4 states (Other, California, New Jersey).
Frequently Asked Questions
What is clinical trial NCT07368998 about?
NCT07368998 is a clinical study titled "To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer". The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (LA/mBC) in the post-cy...
What is the current status of trial NCT07368998?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2026-02-18. Estimated completion is 2031-10-31.
What conditions does trial NCT07368998 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT07368998?
The interventions under investigation include: Fulvestrant (DRUG), Inavolisib (DRUG).
Who is sponsoring clinical trial NCT07368998?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07368998 being conducted?
This trial has 14 study locations across California, New Jersey, Istanbul. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07368998's enrollment target sits among peer trials
80 649th of 1224 higher than 566 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI